Author

K. Sliepen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6 Microbiology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:drug response / drug discovery· 5 Assay:proteomics· 5 Research Focus:cell type annotation· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Approach:genetic perturbation / CRISPR· 2 Research Focus:protein folding & dynamics· 2

Frequent Co-Authors

R. W. Sanders· 7 shared J. A. Burger· 6 shared A. B. Ward· 5 shared I. Bontjer· 5 shared M. Claireaux· 5 shared G. Kerster· 4 shared J. D. Allen· 4 shared M. Brinkkemper· 4 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

R. W. Sanders

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual

D. Guerra, T. Beaumont, L. Radic, G. Kerster, K. van der Straten, M. Yuan, J. L. Torres, W.-H. Lee, H. Liu, M. Poniman, I. Bontjer, J. A. Burger, M. Claireaux, T. G. Caniels, J. L. Snitselaar, , M. J. van Gils

This study identifies broadly neutralizing monoclonal and bispecific antibodies from a Gamma variant-infected individual that effectively neutralize multiple SARS-CoV-2 variants.

iScience · Oct 1, 2023Peer-reviewedImmunology

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines

I. del Moral-Sanchez, E. G. Wee, Y. Xian, W.-H. Lee, J. D. Allen, A. Torrents de la Pena, R. d. P. F. Rocha, J. Ferguson, A. N. Leon, S. Koekkoek, E. E. Schermer, J. A. Burger, S. Kumar, R. Zwolsman, M. Brinkkemper, , R. W. Sanders

The paper introduces a triple tandem trimer (TTT) design for HIV-1 Env and influenza HA immunogens, showing improved trimer-specific immune responses in viral vectored vaccines.

bioRxiv · Aug 27, 2023Microbiology

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

L. Radic, K. Sliepen, V. Yin, M. Brinkkemper, J. Capella-Pujol, A. I. Schriek, J. L. Torres, S. Bangaru, J. A. Burger, M. Poniman, I. Bontjer, J. H. Bouhuijs, D. Gideonse, D. Eggink, A. B. Ward, , J. Schinkel

This study shows bispecific antibodies combine the neutralizing breadth and potency of parental antibodies to neutralize SARS-CoV and SARS-CoV-2 variants, including Omicron.

bioRxiv · Nov 11, 2022Immunology

Lassa virus glycoprotein nanoparticles elicit a neutralizing antibody that defines a new site of vulnerability

P. J. M. Brouwer, A. Antanasijevic, A. J. Ronk, H. Mulller-Krauter, Y. Watanabe, M. Claireaux, N. M. Lloyd, T. P. L. Bijl, H. R. Perrett, T. H. Steijaert, J. A. Burger, M. M. van Haaren, K. Sliepen, M. van Gils, M. Crispin, , R. W. Sanders

This study develops Lassa virus glycoprotein nanoparticles that stabilize GPC trimers and elicit neutralizing antibodies targeting a new vulnerability site.

bioRxiv · Mar 28, 2022 · PreprintImmunology

Structure of the hepatitis C virus E1E2 glycoprotein complex

A. Torrents de la Pena, K. Sliepen, L. Eshun-Wilson, M. Newby, J. D. Allen, S. Koekkoek, I. Zon, A. Chumbe, M. Crispin, J. Schinkel, G. C. Lander, R. W. Sanders, A. B. Ward

The paper presents the cryo-EM structure of the HCV E1E2 glycoprotein complex with antibodies, revealing the E1-E2 interface and its stabilization mechanisms.

bioRxiv · Dec 16, 2021 · PreprintImmunology

A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike

M. Claireaux, T. G. Caniels, M. de Gast, J. Han, D. Guerra, G. Kerster, B. D. van Schaik, A. Jongejan, A. I. Schriek, M. Grobben, P. J. Brouwer, K. van der Straten, Y. Aldon, J. Capella-Pujol, J. L. Snitselaar, , M. J. van Gils

The paper identifies a novel S2 epitope recognized by a public antibody class in SARS-CoV-2-reactive B cells, which becomes exposed on vaccine-optimized spike proteins.

bioRxiv · Dec 1, 2021Immunology

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

P. J. M. Brouwer, M. Brinkkemper, P. Maisonnasse, N. Dereuddre-Bosquet, M. Grobben, M. Claireaux, M. de Gast, R. Marlin, V. Chesnais, S. Diry, J. D. Allen, Y. Watanabe, J. M. Griezen, G. Kerster, H. L. Turner, , de Bree

This paper develops a two-component spike nanoparticle vaccine that protects macaques from SARS-CoV-2 infection by inducing strong neutralizing antibodies and reducing viral replication.

bioRxiv · Nov 7, 2020Immunology

Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

R. Derking, J. D. Allen, C. Cottrell, K. Sliepen, G. E. Seabright, W.-H. Lee, K. Rantalainen, A. Antanasijevic, J. Copps, A. Yasmeen, P. van der Woude, S. W. de Taeye, T. L. G. M. van den Kerkhof, P. J. Klasse, G. Ozorowski, , R. W. Sanders

The paper modifies HIV-1 Env trimers to increase glycan occupancy and reduce artificial glycan holes, improving vaccine antigen design.

bioRxiv · Jul 2, 2020Biochemistry

Optimised cell systems for the investigation ofhepatitis C virus E1E2 glycoproteins

M. D. Kalemera, J. Capella-Pujol, A. Chumbe, A. Underwood, R. A. Bull, J. Schinkel, K. Sliepen, J. Grove

This paper identifies an optimized cell line for producing HCV pseudoparticles and reveals antigenic differences between sE2 produced in 293T and 293F cells.

bioRxiv · Jun 18, 2020 · PreprintMicrobiology

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

P. Brouwer, T. Caniels, K. van Straten, J. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, N. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. van Haaren, D. Guerra, J. Burger, E. Schermer, , M. van Gils

This study isolates potent neutralizing antibodies from COVID-19 patients that target multiple sites on the SARS-CoV-2 spike protein, offering insights for vaccine design and therapeutic development.

bioRxiv · May 12, 2020Microbiology